All animals were housed and treated in accordance with protocols approved by institutional authorities, in agreement with the European Community Directives (2013/63/EEC) and the Italian Law.
SKOV3.ip xenografts were subcutaneously implanted in 4–5 week old immunodeficient (SCID) female mice (Harlan Udine, Italy) as described [26 (link)]. MRI and MRS analyses were conducted at 4.7 T on a Varian/Agilent Inova horizontal bore system (Agilent, Palo Alto, USA) using a volume coil as transmitter and a surface coil as receiver (RAPID Biomedical, Rimpar, Germany) according to a reported protocol [26 (link), 27 (link)]. Further details are reported in Supplementary Methods.
Histological analysis of xenograft sections following hematoxylin/eosin (H&E), Ki67 antigen labeling index (for tumor cell proliferation) and HER2 staining was performed on ex vivo specimens [27 (link)].
SKOV3.ip xenografts were subcutaneously implanted in 4–5 week old immunodeficient (SCID) female mice (Harlan Udine, Italy) as described [26 (link)]. MRI and MRS analyses were conducted at 4.7 T on a Varian/Agilent Inova horizontal bore system (Agilent, Palo Alto, USA) using a volume coil as transmitter and a surface coil as receiver (RAPID Biomedical, Rimpar, Germany) according to a reported protocol [26 (link), 27 (link)]. Further details are reported in Supplementary Methods.
Histological analysis of xenograft sections following hematoxylin/eosin (H&E), Ki67 antigen labeling index (for tumor cell proliferation) and HER2 staining was performed on ex vivo specimens [27 (link)].
Free full text: Click here
